RxDoctor Payments Data

Apranta Patel, MD

Cardiovascular Disease · Danbury, CTNPI 1770732364

Payments from drug & device makers

$1,385in general payments, 2019–2025

Across 63 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$369
  • Pfizer$326
  • Johnson & Johnson$85
  • AstraZeneca$66
  • Irhythm Technologies, Inc.$63
  • Boehringer Ingelheim$60
  • plus $417 from 15 others

What the payments were for

  • Food & beverage$1,385100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,385 in reported general payments places this provider in the 45th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$352,638
Medicare patients
1,291
Services billed
4,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban465$583,686
XareltoRivaroxaban96$112,199
JardianceEmpagliflozin61$77,860
Repatha SureclickEvolocumab32$39,656
EntrestoSacubitril/Valsartan20$25,269
Metoprolol Succinate1,155$21,284
FarxigaDapagliflozin Propanediol31$20,206
Losartan Potassium571$6,610
Atorvastatin Calcium467$6,378
NexlizetBempedoic Acid/Ezetimibe12$6,307
Amlodipine Besylate605$4,698
Labetalol Hcl117$4,255
Valsartan63$3,664
Ezetimibe73$3,590
Dilt-XrDiltiazem Hcl62$2,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$326$583,686465 claims
Johnson & JohnsonXarelto$85$112,19996 claims
Boehringer IngelheimJardiance$60$77,86061 claims
NovartisEntresto$14$25,26920 claims
AstraZenecaFarxiga$66$20,20631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →